Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus ...

Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...

Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.

Abbott’s device business has been a bright spot as litigation over its baby formula products and declining demand for its ...

Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at Royal Bank of Canada in a report issued on Tuesday,Benzinga reports. They ...

Ameritas Advisory Services LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 4.3% in the ...

Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.